Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sanofi SA (SNY) vs Wolfspeed Inc (WOLF) Price & Performance

Wolfspeed IncTrade

Price performance (Past 24H)

Key statistics

Sanofi SA vs Wolfspeed Inc — how do they compare? Sanofi SA trades at $40.04 (market cap $95.18B), while Wolfspeed Inc trades at $30.5 (market cap $1.64B). The key difference: Sanofi SA is far larger — about 58× Wolfspeed Inc's market cap, and Sanofi SA pays a 6.01% dividend while Wolfspeed Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Wolfspeed Inc for 19 Days on average.

SNYWOLF
Market Cap
$95.18B$1.64B
Volume
2,995,64622,772,687
Sector
HealthTechnology
52-Week High
$52.34$73.68
52-Week Low
$39.51$14.80
Typical Hold Time
94 Days19 Days
Enterprise Value
$114.48B$2.35B
Dividend Yield
6.01%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sanofi SA

Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.

The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.

Wolfspeed Inc

Wolfspeed (WOLF) trades at $30.62, down 2.39% today, with a bullish technical signal supported by moving averages. The company shows improving quarterly earnings performance with recent beats, though 2025 fundamentals reveal significant losses (-$1.61B net income) and negative margins. Recent news highlights expansion of 200mm silicon carbide substrates and AI infrastructure exposure. Analyst consensus price target sits at $54.32, representing 77% upside potential from current levels.

Wolfspeed presents a high-risk, high-reward opportunity with strong analyst upside potential but substantial fundamental challenges. The company's path to profitability depends on successful execution of its silicon carbide technology roadmap and achieving breakeven revenue targets. Near-term volatility is expected given ongoing operational challenges and investor investigations, while long-term prospects hinge on AI infrastructure adoption.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SNY
35% Buy65% Sell
Avg holding period · 94 Days
WOLF
1% Buy99% Sell
Avg holding period · 19 Days

Top news

Latest headlines on both assets

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY →

About Wolfspeed Inc

Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.

Read more on WOLF →